Table 2.
The selection of N-glycans that had significant differences from the control group across the disease stages and controls (the entire set is provided in Supplementary Table S1).
| Glycan Peak | Bilateral AMD (B) | Unilateral AMD (U) | Early-Onset Drusen (e) | Controls (c) | p (F) | Pair-Wise Significance ** |
|---|---|---|---|---|---|---|
| GP2 * | 4.13 ± 1.23 (1.90–7.14) | 4.35 ± 1.25 (3.01–6.37) | 2.75 ± 0.81 (1.59–4.66) | 3.74 ± 1.39 (1.06–12.65) | 0.009 (3.84) | -; -; 0.033 |
| GP6 * | 3.44 ± 0.74 (2.13–4.91) | 3.78 ± 0.51 (3.27–4.85) | 4.28 ± 1.00 (2.82–6.41) | 3.77 ± 0.91 (1.49–7.39) | 0.043 (2.72) | |
| GP7 | 11.97 ± 4.08 (8.32–26.34) | 10.01 ± 1.1 (8.17–11.42) | 10.00 ± 1.26 (8.14–13.15) | 10.75 ± 2.42 (6.53–29.18) | 0.038 (2.82) | |
| GP8 * | 8.8 ± 1.19 (6.06–11.01) | 9.42 ± 0.87 (7.86–10.39) | 10.43 ± 2.10 (7.45–16.51) | 9.41 ± 1.55 (5.74–14.93) | 0.016 (3.45) | |
| DG12 | 0.93 ± 0.46 (0.42–2.29) | 0.78 ± 0.20 (0.36–1.06) | 0.73 ± 0.25 (0.39–1.14) | 0.75 ± 0.30 (0.10–2.46) | 0.029 (3.03) | 0.017; -; - |
| DG13 | 0.95 ± 0.57 (0.32–2.30) | 0.70 ± 0.19 (0.34–0.97) | 0.60 ± 0.24 (0.28–1.15) | 0.68 ± 0.28 (0.18–1.95) | <0.001 (7.75) | <0.001; -; - |
| G0 | 4.48 ± 1.20 (2.23–7.38) | 4.67 ± 1.18 (3.41–6.76) | 3.01 ± 0.81 (1.77–4.83) | 4.07 ± 1.36 (1.39–12.84) | 0.004 (4.42) | -; -; 0.017 |
| IgG_GP3 | 0.12 ± 0.02 (0.08–0.15) | 0.11 ± 0.05 (0.04–0.18) | 0.08 ± 0.01 (0.07–0.09) | 0.10 ± 0.03 (0.03–0.18) | 0.049 (3.05) | |
| IgG_GP4 | 25.22 ± 5.54 (13.66–39.43) | 22.52 ± 4.02 (18.57–29.68) | 16.19 ± 4.88 (6.93–23.3) | 20.99 ± 6.14 (6.48–47.89) | <0.001 (9.69) | <0.001; -; 0.004; |
| IgG_GP6 | 6.58 ± 1.60 (4.60–12.08) | 6.37 ± 1.35 (4.78–8.93) | 4.43 ± 1.10 (2.42–6.17) | 5.61 ± 1.63 (2.10–12.86) | <0.001 (8.17) | 0.003; 0.019; 0.010 |
| IgG_GP14 | 9.75 ± 2.51 (4.81–17.54) | 9.30 ± 2.29 (6.84–13.72) | 14.59 ± 3.45 (8.74–20.94) | 11.6 ± 3.67 (3.39–25.82) | <0.001 (8.50) | <0.001; 0.002; 0.002 |
| IgG_GP15 | 1.41 ± 0.28 (0.76–2.31) | 1.50 ± 0.23 (1.14–1.80) | 1.76 ± 0.38 (1.14–2.49) | 1.55 ± 0.36 (0.75–3.54) | 0.009 (3.85) | |
| IgG_GP18 | 7.69 ± 1.63 (4.39–12.05) | 7.20 ± 1.51 (5.05–9.86) | 11.27 ± 2.65 (6.47–17.31) | 9.07 ± 2.53 (3.29–19.38) | <0.001 (10.06) | 0.008; -; 0.001 |
| IgG_GP23 | 1.83 ± 0.57 (0.86–3.43) | 1.79 ± 0.34 (1.18–2.23) | 2.25 ± 0.50 (1.31–3.32) | 2.07 ± 0.63 (0.70–4.67) | 0.040 (2.79) |
* the glycan structure in these peaks correspond to peaks DG2, DG6 and DG8, which were removed from this Table since they were equal to the corresponding GP peaks; ** pair-wise comparisons across groups, where the first value denotes the comparison of bilateral AMD with controls, the second unilateral vs. controls, and the third one is the post-hoc test for the early onset vs. controls; significant values are shown.